Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus LEVORA 0 15 30 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus LEVORA 0 15 30 21.
ENOVID-E vs LEVORA 0.15/30-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive